Newly released data from Chugai Pharmaceuticals shows their drug candidate DONQ52 potently blocks gluten-specific t-cells and is ready for continued development. So, what does this mean for the celiac disease community?
Continue ReadingThe ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.
Continue ReadingThe ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.
Continue ReadingThe first mice with characteristics of celiac disease have been developed at the University of Chicago Celiac Disease Center. For the first time researchers can observe celiac disease onset as the mouse’s immune system launches a coordinated attack against gluten.
Continue ReadingResults from a new study suggest that cell immunity in the bowel is irreversibly altered by celiac disease. Early diagnosis and treatment of celiac disease may be able to save some of these beneficial cells and prevent additional permanent damage.
Continue ReadingLast month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...